---
title: "This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296352846.md"
description: "Wall Street analysts initiated coverage on five biotech and tech stocks with bullish or neutral outlooks. BMO's David Lebowitz rated Alnylam (ALNY) Outperform ($318 PT), BioMarin (BMRN) Outperform ($98 PT), and Ionis (IONS) Market Perform ($60 PT). Cantor Fitzgerald rated AgomAb (AGMB) Overweight, while CLSA rated KE Holdings (BEKE) Outperform ($23.8 PT). These initiations reflect updated analyst opinions on the respective companies."
datetime: "2026-08-19T11:55:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296352846.md)
  - [en](https://longbridge.com/en/news/296352846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296352846.md)
generator: "portal-rs"
---

# This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   BMO Capital analyst David Lebowitz initiated coverage on **Alnylam Pharmaceuticals, Inc.** (NASDAQ:ALNY) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock.
-   Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on **Agomab Therapeutics NV** (NASDAQ:AGMB) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock.
-   BMO Capital analyst David Lebowitz initiated coverage on **Biomarin Pharmaceutical Inc** (NASDAQ:BMRN) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock.
-   CLSA analyst Alvin Huang initiated coverage on **KE Holdings Inc – ADR** (NYSE:BEKE) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock.
-   BMO Capital analyst David Lebowitz initiated coverage on **Ionis Pharmaceuticals Inc** (NASDAQ:IONS) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock.

Considering buying ALNY stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [BEKE.US](https://longbridge.com/en/quote/BEKE.US.md)
- [AGMB.US](https://longbridge.com/en/quote/AGMB.US.md)
- [02423.HK](https://longbridge.com/en/quote/02423.HK.md)

## Related News & Research

- [If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297373977.md)
- [Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility](https://longbridge.com/en/news/297493563.md)
- [BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics](https://longbridge.com/en/news/297679488.md)
- [US FDA approves Ionis Pharma's therapy to treat rare brain disorder](https://longbridge.com/en/news/297955261.md)
- [Ionis Drug Wins FDA Approval as First Alexander Disease Treatment](https://longbridge.com/en/news/298038703.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**